Exclusive first look: The efficacy of lorlatinib, the latest product to be launched in 2024, is revealed!

As a new generation of ALK (tyrosine kinase) inhibitor, Lorlatinib has shown remarkable efficacy in clinical trials, especially in the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). The efficacy of lorlatinib will be elaborated below through comprehensive clinical trial data.

1. Significant advantages in first-line treatment:CROWN study is an important clinical trial on lorlatinib in first-line treatment. The study results show that compared with the traditional ALK inhibitor crizotinib, lorlatinib is more effective in prolonging progression-free survival (PFS). Specifically, the CROWN study observed ALK-positive NSCLC patients. The results showed that the median PFS of the lorlatinib treatment group was significantly longer than that of the crizotinib treatment group, providing patients with more durable disease control.

2. Effective response to drug resistance: Lorlatinib not only performs well in first-line treatment, but also shows certain advantages in dealing with drug resistance. Some patients may develop resistance after receiving traditional ALK inhibitors, and lorlatinib is designed to overcome this situation. Clinical trial data show that for some patients who have been treated with crizotinib and developed resistance, the use of lorlatinib can still achieve better therapeutic effects and prolong PFS, providing new treatment opportunities for these patients.

3. Unique advantage of breaking through the blood-brain barrier: Lorlatinib has the property of breaking through the blood-brain barrier, making it unique in the treatment of NSCLC patients with brain metastasis. Brain metastasis is one of the common complications in patients with lung cancer, and lorlatinib can cross the blood-brain barrier and effectively inhibit the growth of cancer cells in the brain, providing new treatment hope for this urgent problem.

4. Potential improvement in overall survival: Although data on first-line treatment and drug resistance are important manifestations of the efficacy of lorlatinib, more time is needed to observe overall survival (OS) changes. There is no long-term data on the overall survival of lorlatinib in current clinical trials, but based on the significant improvement in PFS currently observed, scientists and doctors are full of expectations that lorlatinib may play a positive role in improving overall survival.

5. Management and balancing of side effects: Clinical trial data also cover the safety and tolerability of lorlatinib. Some patients may experience side effects such as visual disturbances and gastrointestinal discomfort while using lorlatinib. However, these side effects are usually manageable, and with timely management and dosage adjustments, the efficacy of the drug and the patient's quality of life can be balanced.

Overall, the efficacy data of lorlatinib show very positive trends, especially in first-line treatment and in dealing with drug resistance. With the accumulation of more research and data, lorlatinib is expected to become an important treatment option for patients with ALKpositive NSCLC and contribute to improving patients' survival rate and quality of life.

Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For specific medical insurance reimbursement prices, please consult the local hospital pharmacy. There are original lorlatinib drugs and cheaper generic drugs abroad. The cheaper ones are the original drug from Turkey, which costs more than 1,000 yuan, and the original drug from Hong Kong, China, which costs about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.